Literature DB >> 21476867

Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors.

Steven J Gray1, Stacey B Foti, Joel W Schwartz, Lavanya Bachaboina, Bonnie Taylor-Blake, Jennifer Coleman, Michael D Ehlers, Mark J Zylka, Thomas J McCown, R Jude Samulski.   

Abstract

With the increased use of small self-complementary adeno-associated viral (AAV) vectors, the design of compact promoters becomes critical for packaging and expressing larger transgenes under ubiquitous or cell-specific control. In a comparative study of commonly used 800-bp cytomegalovirus (CMV) and chicken β-actin (CBA) promoters, we report significant differences in the patterns of cell-specific gene expression in the central and peripheral nervous systems. The CMV promoter provides high initial neural expression that diminishes over time. The CBA promoter displayed mostly ubiquitous and high neural expression, but substantially lower expression in motor neurons (MNs). We report the creation of a novel hybrid form of the CBA promoter (CBh) that provides robust long-term expression in all cells observed with CMV or CBA, including MNs. To develop a short neuronal promoter to package larger transgenes into AAV vectors, we also found that a 229-bp fragment of the mouse methyl-CpG-binding protein-2 (MeCP2) promoter was able to drive neuron-specific expression within the CNS. Thus the 800-bp CBh promoter provides strong, long-term, and ubiquitous CNS expression whereas the MeCP2 promoter allows an extra 570-bp packaging capacity, with low and mostly neuronal expression within the CNS, similar to the MeCP2 transcription factor.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21476867      PMCID: PMC3177952          DOI: 10.1089/hum.2010.245

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  30 in total

1.  Inducible long-term gene expression in brain with adeno-associated virus gene transfer.

Authors:  R P Haberman; T J McCown; R J Samulski
Journal:  Gene Ther       Date:  1998-12       Impact factor: 5.250

Review 2.  Immune responses to gene therapy vectors: influence on vector function and effector mechanisms.

Authors:  N Bessis; F J GarciaCozar; M-C Boissier
Journal:  Gene Ther       Date:  2004-10       Impact factor: 5.250

3.  Efficient selection for high-expression transfectants with a novel eukaryotic vector.

Authors:  H Niwa; K Yamamura; J Miyazaki
Journal:  Gene       Date:  1991-12-15       Impact factor: 3.688

4.  Definition of an efficient synthetic poly(A) site.

Authors:  N Levitt; D Briggs; A Gil; N J Proudfoot
Journal:  Genes Dev       Date:  1989-07       Impact factor: 11.361

5.  Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis.

Authors:  D M McCarty; P E Monahan; R J Samulski
Journal:  Gene Ther       Date:  2001-08       Impact factor: 5.250

6.  Influence of promoter and WHV post-transcriptional regulatory element on AAV-mediated transgene expression in the rat brain.

Authors:  J C Paterna; T Moccetti; A Mura; J Feldon; H Büeler
Journal:  Gene Ther       Date:  2000-08       Impact factor: 5.250

7.  Differential transgene expression in brain cells in vivo and in vitro from AAV-2 vectors with small transcriptional control units.

Authors:  S Kügler; P Lingor; U Schöll; S Zolotukhin; M Bähr
Journal:  Virology       Date:  2003-06-20       Impact factor: 3.616

8.  Mild overexpression of MeCP2 causes a progressive neurological disorder in mice.

Authors:  Ann L Collins; Jonathan M Levenson; Alexander P Vilaythong; Ronald Richman; Dawna L Armstrong; Jeffrey L Noebels; J David Sweatt; Huda Y Zoghbi
Journal:  Hum Mol Genet       Date:  2004-09-06       Impact factor: 6.150

9.  Dose and promoter effects of adeno-associated viral vector for green fluorescent protein expression in the rat brain.

Authors:  Ronald L Klein; Mary E Hamby; Yan Gong; Aaron C Hirko; Samuel Wang; Jeffrey A Hughes; Michael A King; Edwin M Meyer
Journal:  Exp Neurol       Date:  2002-07       Impact factor: 5.330

10.  Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo.

Authors:  D M McCarty; H Fu; P E Monahan; C E Toulson; P Naik; R J Samulski
Journal:  Gene Ther       Date:  2003-12       Impact factor: 5.250

View more
  134 in total

Review 1.  Gene therapy for the neurological manifestations in lysosomal storage disorders.

Authors:  Seng H Cheng
Journal:  J Lipid Res       Date:  2014-03-29       Impact factor: 5.922

Review 2.  Current prospects and challenges for epilepsy gene therapy.

Authors:  Marc S Weinberg; Thomas J McCown
Journal:  Exp Neurol       Date:  2011-10-08       Impact factor: 5.330

3.  Transduction of the central nervous system after intracerebroventricular injection of adeno-associated viral vectors in neonatal and juvenile mice.

Authors:  Shervin Gholizadeh; Sujeenthar Tharmalingam; Margarita E Macaldaz; David R Hampson
Journal:  Hum Gene Ther Methods       Date:  2013-08-03       Impact factor: 2.396

4.  Mechanism-based combination treatment dramatically increases therapeutic efficacy in murine globoid cell leukodystrophy.

Authors:  Jacqueline A Hawkins-Salsbury; Lauren Shea; Xuntian Jiang; Daniel A Hunter; A Miguel Guzman; Adarsh S Reddy; Elizabeth Y Qin; Yedda Li; Steven J Gray; Daniel S Ory; Mark S Sands
Journal:  J Neurosci       Date:  2015-04-22       Impact factor: 6.167

Review 5.  Comparison of high-dose intracisterna magna and lumbar puncture intrathecal delivery of AAV9 in mice to treat neuropathies.

Authors:  Rachel M Bailey; Alejandra Rozenberg; Steven J Gray
Journal:  Brain Res       Date:  2020-04-11       Impact factor: 3.252

6.  A novel role for brain interleukin-6: facilitation of cognitive flexibility in rat orbitofrontal cortex.

Authors:  Jennifer J Donegan; Milena Girotti; Marc S Weinberg; David A Morilak
Journal:  J Neurosci       Date:  2014-01-15       Impact factor: 6.167

7.  Longitudinal In Vivo Monitoring of the CNS Demonstrates the Efficacy of Gene Therapy in a Sheep Model of CLN5 Batten Disease.

Authors:  Nadia L Mitchell; Katharina N Russell; Martin P Wellby; Hollie E Wicky; Lucia Schoderboeck; Graham K Barrell; Tracy R Melzer; Steven J Gray; Stephanie M Hughes; David N Palmer
Journal:  Mol Ther       Date:  2018-07-17       Impact factor: 11.454

8.  Autonomous parvoviruses neither stimulate nor are inhibited by the type I interferon response in human normal or cancer cells.

Authors:  Justin C Paglino; Wells Andres; Anthony N van den Pol
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

9.  Characterization of a novel adeno-associated viral vector with preferential oligodendrocyte tropism.

Authors:  S K Powell; N Khan; C L Parker; R J Samulski; G Matsushima; S J Gray; T J McCown
Journal:  Gene Ther       Date:  2016-09-15       Impact factor: 5.250

10.  Novel Vector Design and Hexosaminidase Variant Enabling Self-Complementary Adeno-Associated Virus for the Treatment of Tay-Sachs Disease.

Authors:  Subha Karumuthil-Melethil; Sahana Nagabhushan Kalburgi; Patrick Thompson; Michael Tropak; Michael D Kaytor; John G Keimel; Brian L Mark; Don Mahuran; Jagdeep S Walia; Steven J Gray
Journal:  Hum Gene Ther       Date:  2016-07       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.